Irritable Bowel Syndrome Treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019–2026
- ALL3757746
- 250 Pages
- January 2020
- Healthcare
Irritable bowel syndrome is a gastrointestinal disorder of gut that may be identified by colon muscle contraction. It majorly affects the large intestine. In addition, it is associated with the malfunction of the bowel, and majorly occurs in geriatric population. Diarrhea, constipation, alteration & discomfort in bowel function, bloating, and abdominal pain are some of the common symptoms of irritable bowel syndrome. Endoscopy and blood test are normally performed to detect this irritable bowel syndrome. Irritable bowel syndrome is classified into three types such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS. Treatment of irritable bowel syndrome include proper medicines, change in diet, stress relief, and counseling. Medicines used in the treatment of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others.
Significant increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, abdominal pain, adoption of sedentary lifestyle, increase in level of stress, and unhealthy diet are the key factors that fuel the growth of the irritable bowel syndrome treatment market. According to the International Foundation for Gastrointestinal Disorders (IFFGD), it was estimated that irritable bowel syndrome affects around 25-45 million in the U.S. in 2016. Moreover, company developing products with symptom specific application and subsequent launches, increase in geriatric population, and rise in awareness programs for irritable bowel syndrome treatment are other factors that contribute toward the growth of the market. Furthermore, rise in prevalence of irritable bowel syndrome in female is expected to further boost the growth of global irritable bowel treatment market during the forecast period. However, high competition among the key players related to pricing and lack of specific treatment which treat all the symptoms of this disorder are expected to hinder the growth of the market.
The irritable bowel syndrome treatment market is segmented into type, product, end user, and region. Depending on type, the market is categorized into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. On the basis of product, the market is classified into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. On the basis of end user, the market is divided into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Type
• IBS with Diarrhea (IBS-D)
• IBS with Constipation (IBS-C)
• Mixed IBS
By Product
• Rifaximin
• Eluxadoline
• Lubiprostone
• Linaclotide
• Others
By End User
• Hospitals Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Abbott Laboratories
• Allergan plc
• Ardelyx Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• GlaxoSmithKline Plc
• Johnson & Johnson (McNeil Consumer Healthcare)
• Novartis AG
• Sebela Pharmaceuticals Inc.
• Takeda Pharmaceutical Company Ltd.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Bausch Health
• Synthetic Biologics, Inc.
• Callisto Pharmaceuticals, Inc. (Synergy Pharmaceuticals)
• Ironwood Pharmaceuticals, Inc.
• Lexicon Pharmaceuticals, Inc.
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in geriatric population
3.4.1.2. Rise in prevalence of gastrointestinal disorders
3.4.1.3. Increase in number of pipeline drugs
3.4.2. Restrains
3.4.2.1. Poor demand in under developed countries
3.4.3. Opportunities
3.4.3.1. Untapped opportunities in developing economies
3.4.4. Impact analysis
CHAPTER 4: IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. IBS with Diarrhea (IBS-D)
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. IBS with Constipation (IBS-C)
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Mixed-presentation IBS (IBS-M)
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT
5.1. Overview
5.1.1. Market size and forecast
5.2. Rifaximin
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Eluxadoline
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Lubiprostone
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Linaclotide
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Others
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
CHAPTER 6: IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals pharmacies
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Drug Stores and Retail Pharmacies
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Online pharmacies
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. irritable bowel syndrome treatment market, by type
7.2.2.1.2. U.S. irritable bowel syndrome treatment market, by product
7.2.2.1.3. U.S. irritable bowel syndrome treatment market, by end user
7.2.2.2. Canada
7.2.2.2.1. Canada irritable bowel syndrome treatment market, by type
7.2.2.2.2. Canada irritable bowel syndrome treatment market, by product
7.2.2.2.3. Canada irritable bowel syndrome treatment market, by end user
7.2.2.3. Mexico
7.2.2.3.1. Mexico irritable bowel syndrome treatment market, by type
7.2.2.3.2. Mexico irritable bowel syndrome treatment market, by product
7.2.2.3.3. Mexico irritable bowel syndrome treatment market, by end user
7.2.3. North America market size and forecast, by type
7.2.4. North America market size and forecast, by product
7.2.5. North America market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany irritable bowel syndrome treatment market, by type
7.3.2.1.2. Germany irritable bowel syndrome treatment market, by product
7.3.2.1.3. Germany irritable bowel syndrome treatment market, by end user
7.3.2.2. France
7.3.2.2.1. France irritable bowel syndrome treatment market, by type
7.3.2.2.2. France irritable bowel syndrome treatment market, by product
7.3.2.2.3. France irritable bowel syndrome treatment market, by end user
7.3.2.3. UK
7.3.2.3.1. UK irritable bowel syndrome treatment market, by type
7.3.2.3.2. UK irritable bowel syndrome treatment market, by product
7.3.2.3.3. UK irritable bowel syndrome treatment market, by end user
7.3.2.4. Italy
7.3.2.4.1. Italy irritable bowel syndrome treatment market, by type
7.3.2.4.2. Italy irritable bowel syndrome treatment market, by product
7.3.2.4.3. Italy irritable bowel syndrome treatment market, by end user
7.3.2.5. Spain
7.3.2.5.1. Spain irritable bowel syndrome treatment market, by type
7.3.2.5.2. Spain irritable bowel syndrome treatment market, by product
7.3.2.5.3. Spain irritable bowel syndrome treatment market, by end user
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe irritable bowel syndrome treatment market, by type
7.3.2.6.2. Rest of Europe irritable bowel syndrome treatment market, by product
7.3.2.6.3. Rest of Europe irritable bowel syndrome treatment market, by end user
7.3.3. Europe market size and forecast, by type
7.3.4. Europe market size and forecast, by product
7.3.5. Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan irritable bowel syndrome treatment market, by type
7.4.2.1.2. Japan irritable bowel syndrome treatment market, by product
7.4.2.1.3. Japan irritable bowel syndrome treatment market, by end user
7.4.2.2. China
7.4.2.2.1. China irritable bowel syndrome treatment market, by type
7.4.2.2.2. China irritable bowel syndrome treatment market, by product
7.4.2.2.3. China irritable bowel syndrome treatment market, by end user
7.4.2.3. Australia
7.4.2.3.1. Australia irritable bowel syndrome treatment market, by type
7.4.2.3.2. Australia irritable bowel syndrome treatment market, by product
7.4.2.3.3. Australia irritable bowel syndrome treatment market, by end user
7.4.2.4. India
7.4.2.4.1. India irritable bowel syndrome treatment market, by type
7.4.2.4.2. India irritable bowel syndrome treatment market, by product
7.4.2.4.3. India irritable bowel syndrome treatment market, by end user
7.4.2.5. South Korea
7.4.2.5.1. South Korea irritable bowel syndrome treatment market, by type
7.4.2.5.2. South Korea irritable bowel syndrome treatment market, by product
7.4.2.5.3. South Korea irritable bowel syndrome treatment market, by end user
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific irritable bowel syndrome treatment market, by type
7.4.2.6.2. Rest of Asia-Pacific irritable bowel syndrome treatment market, by product
7.4.2.6.3. Rest of Asia-Pacific irritable bowel syndrome treatment market, by end user
7.4.3. Asia-Pacific market size and forecast, by type
7.4.4. Asia-Pacific market size and forecast, by product
7.4.5. Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil irritable bowel syndrome treatment market, by type
7.5.2.1.2. Brazil irritable bowel syndrome treatment market, by product
7.5.2.1.3. Brazil irritable bowel syndrome treatment market, by end user
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia irritable bowel syndrome treatment market, by type
7.5.2.2.2. Saudi Arabia irritable bowel syndrome treatment market, by product
7.5.2.2.3. Saudi Arabia irritable bowel syndrome treatment market, by end user
7.5.2.3. South Africa
7.5.2.3.1. South Africa irritable bowel syndrome treatment market, by type
7.5.2.3.2. South Africa irritable bowel syndrome treatment market, by product
7.5.2.3.3. South Africa irritable bowel syndrome treatment market, by end user
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA irritable bowel syndrome treatment market, by type
7.5.2.4.2. Rest of LAMEA irritable bowel syndrome treatment market, by product
7.5.2.4.3. Rest of LAMEA irritable bowel syndrome treatment market, by end user
7.5.3. LAMEA market size and forecast, by type
7.5.4. LAMEA market size and forecast, by product
7.5.5. LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Allergan plc
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Ardelyx Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Astellas Pharma Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. AstraZeneca plc
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. GlaxoSmithKline Plc
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Johnson & Johnson (McNeil Consumer Healthcare)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. Novartis AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Sebela Pharmaceuticals Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. Takeda Pharmaceutical Company Ltd.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
TABLE 01. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 02. IBS WITH DIARRHEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. IBS WITH CONSTIPATION IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, (2018–2026 ($MILLION)
TABLE 04. MIXED IBS IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 06. RIFAXIMIN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. ELUXADOLINE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. LUBIPROSTONE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. LINACLOTIDE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. OTHERS GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 12. IRRITABLE BOWEL SYNDROME TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 13. IRRITABLE BOWEL SYNDROME TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 14. IRRITABLE BOWEL SYNDROME TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 15. IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 16. NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 17. U.S. IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 18. U.S. IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 19. U.S. IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 20. CANADA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 21. CANADA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 22. CANADA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 23. MEXICO IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 24. MEXICO IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 25. MEXICO IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 26. NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 27. NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 28. NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 29. EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 30. GERMANY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 31. GERMANY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 32. GERMANY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 33. FRANCE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 34. FRANCE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 35. FRANCE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 36. UK IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 37. UK IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 38. UK IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 39. ITALY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 40. ITALY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 41. ITALY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 42. SPAIN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 43. SPAIN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 44. SPAIN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 45. REST OF EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 46. REST OF EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 47. REST OF EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 48. EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 49. EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 50. EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 51. ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 52. JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 53. JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 54. JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 55. CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 56. CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 57. CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 58. AUSTRALIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 59. AUSTRALIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 60. AUSTRALIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 61. INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 62. INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 63. INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 64. SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 65. SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 66. SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 67. REST OF ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 68. REST OF ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 69. REST OF ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 70. ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 71. ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 72. ASIA-PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 73. LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 74. BRAZIL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 75. BRAZIL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 76. BRAZIL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 77. SAUDI ARABIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 78. SAUDI ARABIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 79. SAUDI ARABIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 80. SOUTH AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 81. SOUTH AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 82. SOUTH AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 83. REST OF LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 84. REST OF LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 85. REST OF LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 86. LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 87. LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, 2018–2026
TABLE 88. LAMEA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY END USER, 2018–2026
TABLE 89. ABBOTT: COMPANY SNAPSHOT
TABLE 90. ABBOTT: OPERATING SEGMENTS
TABLE 91. ABBOTT: PRODUCT PORTFOLIO
TABLE 92. ALLERGAN: COMPANY SNAPSHOT
TABLE 93. ALLERGAN: OPERATING SEGMENTS
TABLE 94. ALLERGAN: PRODUCT PORTFOLIO
TABLE 95. ARDELYX: COMPANY SNAPSHOT
TABLE 96. ARDELYX: PRODUCT PORTFOLIO
TABLE 97. ASTELLAS: COMPANY SNAPSHOT
TABLE 98. ASTELLAS: PRODUCT PORTFOLIO
TABLE 99. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 100. ASTRAZENECA: OPERATING SEGMENTS
TABLE 101. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 102. GSK: COMPANY SNAPSHOT
TABLE 103. GSK: OPERATING SEGMENTS
TABLE 104. GSK: PRODUCT PORTFOLIO
TABLE 105. J&J: COMPANY SNAPSHOT
TABLE 106. J&J: OPERATING SEGMENTS
TABLE 107. J&J: PRODUCT PORTFOLIO
TABLE 108. NOVARTIS: COMPANY SNAPSHOT
TABLE 109. NOVARTIS: OPERATING SEGMENTS
TABLE 110. NOVARTIS: PRODUCT PORTFOLIO
TABLE 111. SEBELA: COMPANY SNAPSHOT
TABLE 112. SEBELA: PRODUCT PORTFOLIO
TABLE 113. TAKEDA: COMPANY SNAPSHOT
TABLE 114. TAKEDA: PRODUCT PORTFOLIO
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
